Revvity's EUROIMMUN and ALPCO-GeneProof Partnership

• The partnership includes EUROIMMUN's distribution network and support infrastructure, and ALPCO-GeneProof's innovative molecular diagnostic technologies.
• EUROIMMUN will deliver 42 molecular diagnostic assays from ALPCO-GeneProof, based on "one workflow" technology.
• EUROIMMUN will also offer the croBEE^® nucleic acid extraction system.
• GeneProof PCR kits cover various diseases including transplant, STIs, bloodborne pathogens, respiratory infections, thrombotic mutations, neuroinfections, and antibiotic resistance.

Revvity's EUROIMMUN business, a leading provider of high-quality in-vitro diagnostic products, and ALPCO-GeneProof, a global leader in molecular diagnostics, jointly announced a strategic partnership to enhance the availability of GeneProof PCR kits throughout the European Union. This collaboration brings together EUROIMMUN's extensive distribution network and support infrastructure with ALPCO-GeneProof's innovative molecular diagnostic technologies.

The agreement will see EUROIMMUN delivering a comprehensive portfolio of 42 molecular diagnostic assays from ALPCO-GeneProof. These assays are based on the innovative "one workflow" technology, which simplifies use and ensures compatibility with a broad range of qPCR instruments. Additionally, EUROIMMUN will offer the croBEE^® nucleic acid extraction system, further enhancing the diagnostic solutions.

The full menu of GeneProof PCR kits includes assays for transplant and immunocompromised patients, sexually transmitted infections (STIs), bloodborne pathogens, respiratory infections, thrombotic mutations, neuroinfections, and antibiotic resistance.

Visit ALPCO for more or use the Request Information button below to connect directly with the company.